Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

Daniel Kim Views  

Medical Today
Medical Today

Merck & Co. recently revealed its intention to introduce a subcutaneous version of Keytruda, its cancer immunotherapy, to the US market on October 1. The subcutaneous formulation of Keytruda is still awaiting approval from the U.S. Food and Drug Administration (FDA), with a decision expected by September 23.

Merck explained that administering Keytruda via subcutaneous injection, as opposed to intravenous infusion, could significantly reduce the time patients spend receiving treatment.

Merck’s Senior Vice President of Oncology stated in an interview that they plan to ship the product immediately following approval, ensuring sufficient supply to meet market demand within 1-2 weeks.

Keytruda, approved for treating various types of cancer, is currently the world’s best-selling prescription drug. Sales are projected to reach approximately $30 billion in 2024.

Industry experts predict that Merck, which has relied heavily on Keytruda for growth in recent years, could benefit from intellectual property protection for the subcutaneous version before Keytruda’s primary patent expires in 2028. Alteogen, a South Korean pharmaceutical company, is developing and manufacturing an enzyme used in the subcutaneous formulation of Keytruda.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Why Your Eyelid Keeps Twitching—and When to Worry
  • Silent Spreaders: How Measles Can Infect Before Symptoms Appear
  • Eat More Eggplant—It’s Good for Your Blood and Your Heart
  • Want to Burn More Fat? Try a 30-Second Cold Shower, Experts Say
  • Bats, Fruit, and a Deadly Virus—Why Korea’s Health Officials Are on High Alert
  • Why You Crave Junk Food When You’re Sad—And What to Eat Instead

You May Also Like

  • 1
    Trump Claims Epstein 'Stole' Young Women from Mar-a-Lago Spa

    LATEST 

  • 2
    Say Hello to Your New Beauty Buddy: AI-Powered Kiosks Hit GS25 Stores!

    LATEST 

  • 3
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 4
    COP30 Chaos: Will Brazil's Soaring Hotel Prices Keep Poor Nations Out of Climate Talks?

    LATEST 

  • 5
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

Popular Now

  • 1
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 2
    Hydroleap Secures $4.75 Million to Revolutionize Water Treatment in Asia!

    LATEST 

  • 3
    Enhypen's New Single 'Yoi' Soars to the Top, Selling Over 300,000 Copies on Day One!

    LATEST 

  • 4
    Chanyeol of EXO Set to Drop Solo Album This August – Here’s What We Know!

    LATEST 

  • 5
    Caught Between Borders: Texas Man's Harrowing Eight-Day Detention

    LATEST 

Must-Reads

  • 1
    Trump Claims Epstein 'Stole' Young Women from Mar-a-Lago Spa

    LATEST 

  • 2
    Say Hello to Your New Beauty Buddy: AI-Powered Kiosks Hit GS25 Stores!

    LATEST 

  • 3
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 4
    COP30 Chaos: Will Brazil's Soaring Hotel Prices Keep Poor Nations Out of Climate Talks?

    LATEST 

  • 5
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

Popular Now

  • 1
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 2
    Hydroleap Secures $4.75 Million to Revolutionize Water Treatment in Asia!

    LATEST 

  • 3
    Enhypen's New Single 'Yoi' Soars to the Top, Selling Over 300,000 Copies on Day One!

    LATEST 

  • 4
    Chanyeol of EXO Set to Drop Solo Album This August – Here’s What We Know!

    LATEST 

  • 5
    Caught Between Borders: Texas Man's Harrowing Eight-Day Detention

    LATEST 

Share it on...